Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Healthcare sector poised for rebound in 2025
08:00pm, Monday, 13'th Jan 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
GSK CEO on acquisition of biotech firm IDRx
12:39pm, Monday, 13'th Jan 2025
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
Drugmakers rush to sign deals on first day of industry conference
12:07pm, Monday, 13'th Jan 2025
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
GSK swoops for US cancer specialist in $1.15bn deal
03:23am, Monday, 13'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront, in a bid to expand its portfolio of cancer therapies. The deal includ
GSK to buy US biotech firm IDRx for up to $1.15 billion
02:10am, Monday, 13'th Jan 2025
British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
GSK Enters Agreement to Acquire IDRx, Inc.
02:05am, Monday, 13'th Jan 2025
PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-sta
GSK's new shingles jab submitted for review by US regulator
03:40am, Friday, 10'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has announced that the US Food and Drug Administration (FDA) is reviewing its new prefilled syringe version of Shingrix, its shingles vaccine. If approved, the updated del
GSK swooping to buy US biotech IDRx for $1bn - report
10:29am, Wednesday, 08'th Jan 2025
UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of venture capital and priv
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
06:20pm, Tuesday, 07'th Jan 2025
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tu
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
12:57pm, Tuesday, 07'th Jan 2025
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
GSK's experimental cancer drug wins receives support from US regulator
02:42am, Tuesday, 07'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has received a major boost for its experimental drug GSK5764227 (GSK'227), which targets a rare and aggressive bone cancer called osteosarcoma. The US Food and Drug Admini
GSK's Nucala approved in China for treating nasal polyps
02:30am, Friday, 03'rd Jan 2025
GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, ha
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
03:46am, Friday, 20'th Dec 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based
GSK's cancer drugs meet progression-free survival goal in late-stage trial
02:35am, Friday, 20'th Dec 2024
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease
